This trial is testing the side effects and best dose of two drugs, cediranib and olaparib, compared to olaparib alone, in treating patients with recurrent ovarian, fallopian tube, peritoneal, or triple-negative breast cancer.
4 Primary · 4 Secondary · Reporting Duration: Adverse Events monitored for 3 years, mortality assessed up to 5 years
155 Total Participants · 2 Treatment Groups
Primary Treatment: Cediranib Maleate · No Placebo Group · Phase 1 & 2
Age 18+ · Female Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: